Europe’s healthcare M&A is poised to maintain strong momentum in 2026 following this year’s rebound in deal activity and renewed market confidence. “The sector is in a flywheel of productivity with drivers including ageing populations, workforce shortages, and technology adoption,” said Lloyd Price, Partner at Nelson Advisors. Following the turbulent tariff and regulatory environment at the start of 2025, the market is entering a period of relative confidence, he added.

Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity fi